Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: Consensus at the symposium of the 48th annual meeting of the liver cancer study group of Japan

Masatoshi Kudo, Osamu Matsui, Michiie Sakamoto, Azusa Kitao, Tonsok Kim, Shun Ichi Ariizumi, Tomoaki Ichikawa, Satoshi Kobayashi, Yasuharu Imai, Namiki Izumi, Yasunari Fujinaga, Shigeki Arii

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We summarize here the consensus reached at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan held in Kanazawa on July 20th and 21st, 2012, on the role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) in the management of hepatocellular carcinoma (HCC). Currently, dynamic CT is the first choice of imaging modality when HCC is suspected. EOB-MRI is useful for differentiation and definitive diagnosis of HCC when dynamic CT/MRI does not show conclusive findings for HCC. In addition, contrast- enhanced ultrasound with Sonazoid is useful for making a decision on whether or not to treat a hypovascular lesion <1 cm when the nodules are shown with low intensity in the hepatocyte phase of EOB-MRI. Furthermore, EOB-MRI should be performed in selected cases of HCC ultrahigh-risk groups every 3-4 months, or EOB-MRI should be performed at least once at the first visit in all HCC ultrahigh-risk groups.

Original languageEnglish
Pages (from-to)21-27
Number of pages7
JournalOncology (Switzerland)
Volume84
Issue numberSUPPL.1
DOIs
Publication statusPublished - 2013 Feb

Fingerprint

Pentetic Acid
Gadolinium
Liver Neoplasms
Hepatocellular Carcinoma
Consensus
Japan
Magnetic Resonance Imaging
Hepatocytes
Decision Making

Keywords

  • EOB-MRI
  • Expert consensus
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma : Consensus at the symposium of the 48th annual meeting of the liver cancer study group of Japan. / Kudo, Masatoshi; Matsui, Osamu; Sakamoto, Michiie; Kitao, Azusa; Kim, Tonsok; Ariizumi, Shun Ichi; Ichikawa, Tomoaki; Kobayashi, Satoshi; Imai, Yasuharu; Izumi, Namiki; Fujinaga, Yasunari; Arii, Shigeki.

In: Oncology (Switzerland), Vol. 84, No. SUPPL.1, 02.2013, p. 21-27.

Research output: Contribution to journalArticle

Kudo, Masatoshi ; Matsui, Osamu ; Sakamoto, Michiie ; Kitao, Azusa ; Kim, Tonsok ; Ariizumi, Shun Ichi ; Ichikawa, Tomoaki ; Kobayashi, Satoshi ; Imai, Yasuharu ; Izumi, Namiki ; Fujinaga, Yasunari ; Arii, Shigeki. / Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma : Consensus at the symposium of the 48th annual meeting of the liver cancer study group of Japan. In: Oncology (Switzerland). 2013 ; Vol. 84, No. SUPPL.1. pp. 21-27.
@article{7bf7f266d04b48abb99266b5221bed1f,
title = "Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: Consensus at the symposium of the 48th annual meeting of the liver cancer study group of Japan",
abstract = "We summarize here the consensus reached at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan held in Kanazawa on July 20th and 21st, 2012, on the role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) in the management of hepatocellular carcinoma (HCC). Currently, dynamic CT is the first choice of imaging modality when HCC is suspected. EOB-MRI is useful for differentiation and definitive diagnosis of HCC when dynamic CT/MRI does not show conclusive findings for HCC. In addition, contrast- enhanced ultrasound with Sonazoid is useful for making a decision on whether or not to treat a hypovascular lesion <1 cm when the nodules are shown with low intensity in the hepatocyte phase of EOB-MRI. Furthermore, EOB-MRI should be performed in selected cases of HCC ultrahigh-risk groups every 3-4 months, or EOB-MRI should be performed at least once at the first visit in all HCC ultrahigh-risk groups.",
keywords = "EOB-MRI, Expert consensus, Hepatocellular carcinoma",
author = "Masatoshi Kudo and Osamu Matsui and Michiie Sakamoto and Azusa Kitao and Tonsok Kim and Ariizumi, {Shun Ichi} and Tomoaki Ichikawa and Satoshi Kobayashi and Yasuharu Imai and Namiki Izumi and Yasunari Fujinaga and Shigeki Arii",
year = "2013",
month = "2",
doi = "10.1159/000345885",
language = "English",
volume = "84",
pages = "21--27",
journal = "Oncology (Switzerland)",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "SUPPL.1",

}

TY - JOUR

T1 - Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma

T2 - Consensus at the symposium of the 48th annual meeting of the liver cancer study group of Japan

AU - Kudo, Masatoshi

AU - Matsui, Osamu

AU - Sakamoto, Michiie

AU - Kitao, Azusa

AU - Kim, Tonsok

AU - Ariizumi, Shun Ichi

AU - Ichikawa, Tomoaki

AU - Kobayashi, Satoshi

AU - Imai, Yasuharu

AU - Izumi, Namiki

AU - Fujinaga, Yasunari

AU - Arii, Shigeki

PY - 2013/2

Y1 - 2013/2

N2 - We summarize here the consensus reached at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan held in Kanazawa on July 20th and 21st, 2012, on the role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) in the management of hepatocellular carcinoma (HCC). Currently, dynamic CT is the first choice of imaging modality when HCC is suspected. EOB-MRI is useful for differentiation and definitive diagnosis of HCC when dynamic CT/MRI does not show conclusive findings for HCC. In addition, contrast- enhanced ultrasound with Sonazoid is useful for making a decision on whether or not to treat a hypovascular lesion <1 cm when the nodules are shown with low intensity in the hepatocyte phase of EOB-MRI. Furthermore, EOB-MRI should be performed in selected cases of HCC ultrahigh-risk groups every 3-4 months, or EOB-MRI should be performed at least once at the first visit in all HCC ultrahigh-risk groups.

AB - We summarize here the consensus reached at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan held in Kanazawa on July 20th and 21st, 2012, on the role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) in the management of hepatocellular carcinoma (HCC). Currently, dynamic CT is the first choice of imaging modality when HCC is suspected. EOB-MRI is useful for differentiation and definitive diagnosis of HCC when dynamic CT/MRI does not show conclusive findings for HCC. In addition, contrast- enhanced ultrasound with Sonazoid is useful for making a decision on whether or not to treat a hypovascular lesion <1 cm when the nodules are shown with low intensity in the hepatocyte phase of EOB-MRI. Furthermore, EOB-MRI should be performed in selected cases of HCC ultrahigh-risk groups every 3-4 months, or EOB-MRI should be performed at least once at the first visit in all HCC ultrahigh-risk groups.

KW - EOB-MRI

KW - Expert consensus

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84874362178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874362178&partnerID=8YFLogxK

U2 - 10.1159/000345885

DO - 10.1159/000345885

M3 - Article

C2 - 23428854

AN - SCOPUS:84874362178

VL - 84

SP - 21

EP - 27

JO - Oncology (Switzerland)

JF - Oncology (Switzerland)

SN - 0030-2414

IS - SUPPL.1

ER -